NCT07388875 2026-02-05
SKB264-ANLO
China Medical University, China
Phase 2 Not yet recruiting
Clinical Trials
12 trialsNCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting
NCT07358676 2026-01-22
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04660097 2022-04-12
Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT04620837 2020-11-09
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
ChineseAMS
Phase 2 Unknown
NCT04363255 2020-04-28
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Taizhou Hospital
Phase 2 Unknown
NCT04314297 2020-03-19
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT03700359 2019-11-29
A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Unknown
NCT03059797 2019-05-16
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT03841136 2019-03-28
Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer
Fudan University
Phase 2 Unknown
NCT03780283 2018-12-21
Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
First Hospital of Shijiazhuang City
Phase 2 Unknown
NCT03732846 2018-11-07
Anlotinib in Treatment of Recurrent Small Cell Lung Cancer
Peking University Cancer Hospital & Institute
Phase 2 Unknown